Cabaletta Bio Inc. (NASDAQ:CABA) traded with an addition of $1.74 to close at $9.80 on Thursday, an upside of 21.59 percent. An average of 951,525 shares of common stock have been traded in the last five days. There was a gain of $1.23 in the past week, and it reached a new high 11 times over the past 12 months. The last 20 days have seen an average of 1,005,426 shares traded, while the 50-day average volume stands at 1,555,279.
CABA stock has increased by 127.04% in the last month. The company shares reached their 1-month lowest point of $3.88 on 11/30/22. With the stock rallying to its 52-week high on 12/22/22, shares of the company touched a low of $0.59 and a high of $9.86 in 52 weeks. It has reached a new high 11 times so far this year and achieved 112.66% or $5.96 in price. In spite of this, the price is down -0.61% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
The quick ratio of Cabaletta Bio Inc. for the three months ended June 29 was 15.20, and the current ratio was 15.20, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Cabaletta Bio Inc.’s return on assets was -47.20%.
For the three-month period that ended June 29, Cabaletta Bio Inc. had $24.73 million in cash. The company posted a net income of -$11.43 million in the quarter, while revenues of -$12.91 million were grew 2.54%. The analyst consensus anticipated Cabaletta Bio Inc.’s latest quarter earnings to come in at -$0.5 per share, but it turned out to be -$0.45, a 10.00% surprise. At the end of the quarter ending June 29, Cabaletta Bio Inc.’s stock balance sheet showed total liabilities of 5.8 million. Shareholders own equity worth $29.01 million.
From a technical analysis perspective, let’s take a brief look at Cabaletta Bio Inc. (CABA) price momentum. RSI 9-day as of the close on 28 December was 73.10%, suggesting the stock is Overbought, with historical volatility in this time frame at 165.31%.
As of today, CABA’s price is $8.64 +14.44% or $1.23 from its 5-day moving average. CABA is currently trading +117.63% higher than its 20-day SMA and +679.99% higher than its 100-day SMA. However, the stock’s current price level is +883.45% above the SMA50 and +480.35% above the SMA200.
The stochastic %K and %D were 71.41% and 67.64%, respectively, and the average true range (ATR) was 1.16. With the 14-day stochastic at 97.68% and the average true range at 0.99, the RSI (14) stands at 73.19%. The stock has reached 0.49 on the 9-day MACD Oscillator while the 14-day reading was at 1.17.
Morgan Stanley downgraded Cabaletta Bio Inc. (NASDAQ: CABA) to a an Equal-weight rating in its most recent analyst report. Previously, the stock was rated as an Overweight. The consensus rating for Cabaletta Bio Inc. (CABA) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell CABA, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 6 others rate it as a “buy”.
What is CABA’s price target for the next 12 months?
Analysts predict a range of price targets between $3.00 and $14.00, with a median target of $10.50. Taking a look at these predictions, the average price target given by analysts for Cabaletta Bio Inc. (CABA) stock is $9.00.